Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06825260 · ClinicalTrials.gov registry record · Phase 4
PEG3350 vs Senna After Urogyn Surgery
A Phase 4 study of Obstructive Defecation Syndrome and Postoperative Constipation, sponsored by St. Joseph's Health, New York.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 254
- Enrollment target
- 1
- Study location
NCT06825260 is a Phase 4 study of Obstructive Defecation Syndrome and Postoperative Constipation that is actively recruiting participants, run by St. Joseph's Health, New York. The registered enrollment target is 254 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06825260, a Phase 4 study of Obstructive Defecation Syndrome and Postoperative Constipation, is actively recruiting participants, sponsored by St. Joseph's Health, New York.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 254 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to evaluate whether polyethylene glycol 3350 (PEG3350) versus senna is better at relieving postoperative constipation after urogynecologic surgery. The main questions it aims to answer are: What number of patients taking PEG3350 have obstructed defecation syndrome (ODS), a form of constipation, vs those taking senna in the week after urogynecologic surgery? What patient-level and procedure-level characteristics are associated with postoperative ODS, in patients taking PEG3350 vs senna? participants will: Take their randomized medication daily for seven days after surgery Fill out an ODS questionnaire before and one week after surgery Complete a daily bowel diary for 7 days after surgery
Conditions Studied
Interventions
- DRUG Senna
- DRUG Polyethylene glycol 3350
Study Locations (1)
New York
- St. Joseph's Health Hospital - Syracuse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2025-04-23 |
| Est. Completion | 2027-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06825260
The ClinicalTrials.gov registry entry for NCT06825260 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 254 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Joseph's Health, New York, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obstructive Defecation Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Senna is the first listed.
NCT06825260 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06825260 about?
NCT06825260 is a clinical study titled "PEG3350 vs Senna After Urogyn Surgery". The goal of this study is to evaluate whether polyethylene glycol 3350 (PEG3350) versus senna is better at relieving postoperative constipation after urogynecologic surgery. The main questions it aims to answer are: What number of patients taking PEG3350 have obstructed defecation syndrome (ODS), a...
What is the current status of trial NCT06825260?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 254 participants. The study started on 2025-04-23. Estimated completion is 2027-07.
What conditions does trial NCT06825260 study?
This clinical trial studies the following conditions: Obstructive Defecation Syndrome, Postoperative Constipation.
What interventions are being tested in trial NCT06825260?
The interventions under investigation include: Senna (DRUG), Polyethylene glycol 3350 (DRUG).
Who is sponsoring clinical trial NCT06825260?
This trial is sponsored by St. Joseph's Health, New York, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06825260 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.